-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For a long time, immune cell therapy has been controversial, because the previous DC-CIK immune cell therapy, after in vitro expansion, returned to the human body, did not recognize tumor cells well, which led to poor treatment.
effect
.
To this end, there are now gradually new treatment measures
.
That is, the patient's tumor tissue samples are tested accordingly, and the specific antigens of the tumor are analyzed, and then based on this antigen, the immune cells of the human body are searched, and those immune cells can recognize the specific antigen of the tumor
.
This kind of "baby immune cells" is selected for special in vitro expansion, and then returned to the patient's body.
In this case, a very good therapeutic effect can be achieved, and the adverse reactions are relatively mild, most of which are around the second grade.
adverse reactions
.
It is a truly personalized treatment plan
.
Image source: Photo.
cn At present, this treatment measure belongs to the clinical trial stage.
After the patient passes the registration and enrollment, the drug and the corresponding examination fee are exempted
.
No expensive treatment is required
.
To participate in this clinical study, you can search and download the Cancer App, click on clinical trial registration, or click on "Global Clinical Trials" to apply for registration
.
Enrollment requirements 1.
The age is greater than 18 years old and less than 70 years old, and the gender is not limited; 2.
There must be advanced solid tumors diagnosed by histology or cytology, and at least one tumor lesion can be measured; 3.
HLA type is HLA -A0201/1101/2402 (with at least one of these types), the laboratory provides testing; 4.
There are paraffin-embedded tumor tissue/sections or biopsy puncture tissue (tumor lesions that are easy to sample and those who agree to biopsy are recommended Biopsy to obtain tissue), the tissue samples are qualified by gene sequencing data, and the tumor neoantigen screening is qualified; 5.
Systemic standard treatment has been received before enrollment, and there is currently no effective treatment; 6.
Good physical condition
.
Not meeting the requirements for inclusion 1.
Pregnant or breastfeeding women; 2.
Patients with a history of severe immediate hypersensitivity to any drugs used in this study; 3.
Those with a history of organ transplantation; 4.
Known central nervous system metastasis and clinically unstable; 5.
Severe liver and kidney damage; 6.
Defects in genes related to antigen presentation, antigen recognition, and cell killing were detected by sequencing
.
To participate in this clinical study, you can search and download the Cancer App, click on clinical trial registration, or click on "Global Clinical Trials" to apply for registration
.
Click below to learn more about clinical trials
effect
.
To this end, there are now gradually new treatment measures
.
That is, the patient's tumor tissue samples are tested accordingly, and the specific antigens of the tumor are analyzed, and then based on this antigen, the immune cells of the human body are searched, and those immune cells can recognize the specific antigen of the tumor
.
This kind of "baby immune cells" is selected for special in vitro expansion, and then returned to the patient's body.
In this case, a very good therapeutic effect can be achieved, and the adverse reactions are relatively mild, most of which are around the second grade.
adverse reactions
.
It is a truly personalized treatment plan
.
Image source: Photo.
cn At present, this treatment measure belongs to the clinical trial stage.
After the patient passes the registration and enrollment, the drug and the corresponding examination fee are exempted
.
No expensive treatment is required
.
To participate in this clinical study, you can search and download the Cancer App, click on clinical trial registration, or click on "Global Clinical Trials" to apply for registration
.
Enrollment requirements 1.
The age is greater than 18 years old and less than 70 years old, and the gender is not limited; 2.
There must be advanced solid tumors diagnosed by histology or cytology, and at least one tumor lesion can be measured; 3.
HLA type is HLA -A0201/1101/2402 (with at least one of these types), the laboratory provides testing; 4.
There are paraffin-embedded tumor tissue/sections or biopsy puncture tissue (tumor lesions that are easy to sample and those who agree to biopsy are recommended Biopsy to obtain tissue), the tissue samples are qualified by gene sequencing data, and the tumor neoantigen screening is qualified; 5.
Systemic standard treatment has been received before enrollment, and there is currently no effective treatment; 6.
Good physical condition
.
Not meeting the requirements for inclusion 1.
Pregnant or breastfeeding women; 2.
Patients with a history of severe immediate hypersensitivity to any drugs used in this study; 3.
Those with a history of organ transplantation; 4.
Known central nervous system metastasis and clinically unstable; 5.
Severe liver and kidney damage; 6.
Defects in genes related to antigen presentation, antigen recognition, and cell killing were detected by sequencing
.
To participate in this clinical study, you can search and download the Cancer App, click on clinical trial registration, or click on "Global Clinical Trials" to apply for registration
.
Click below to learn more about clinical trials
